MARKET

INSM

INSM

Insmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.03
+0.74
+1.88%
Closed 17:25 02/24 EST
OPEN
39.64
PREV CLOSE
39.29
HIGH
40.21
LOW
38.58
VOLUME
918.69K
TURNOVER
--
52 WEEK HIGH
45.44
52 WEEK LOW
12.09
MARKET CAP
4.08B
P/E (TTM)
-15.4098
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Insmed Q4 EPS $(1.00) Misses $(0.70) Estimate, Sales $41.41M Miss $41.44M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.70) by 42.86 percent. This is a 69.49 percent decrease over losses of $(0.59) per share from the same
Benzinga · 39m ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 50m ago
BRIEF-Insmed Reports Fourth Quarter And Full Year 2020 Results
reuters.com · 1h ago
Insmed EPS misses by $0.29, revenue in-line
Insmed (INSM): Q4 GAAP EPS of -$1.00 misses by $0.29.Revenue of $41.42M (-9.4% Y/Y) in-line.Press Release
Seekingalpha · 1h ago
Notable earnings before Thursday's open
[[AAON]], [[ACIW]], [[AEP]], [[AES]], [[AGIO]], [[AMRN]], [[AMT]], [[AMWD]], [[BBY]], [[BUD]], [[CARS]], [[CCOI]], [[CGEN]], [[CLF]], [[CLVT]], [[CM]], [[CNP]], [[CSTM]], [[CWH]], [[CWT]], [[DCI]], [[DOC]], [[DPZ]], [[EDIT]], [[EME]], [[EVOP]], [[EXLS]], [...
Seekingalpha · 20h ago
Insmed Q4 2020 Earnings Preview
Insmed (NASDAQ:INSM) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is -$0.68 and the consensus Revenue Estimate is $41.44M (-9.3% Y/Y).Over
Seekingalpha · 21h ago
Insmed to Present at Two March Conferences
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events:
PR Newswire · 1d ago
Inhaled Antibiotics Market Growth, Share, Trends and Forecasts 2020 to 2027 By Ameco Research
pune, India, Wed, 24 Feb 2021 02:44:26 / Comserve Inc. / -- This report focuses on Inhaled Antibiotics volume and value at the global level, regional level...
Comserve · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INSM. Analyze the recent business situations of Insmed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INSM stock price target is 52.78 with a high estimate of 60.00 and a low estimate of 43.00.
EPS
Institutional Holdings
Institutions: 327
Institutional Holdings: 121.87M
% Owned: 119.63%
Shares Outstanding: 101.87M
TypeInstitutionsShares
Increased
56
6.54M
New
53
2.49M
Decreased
80
9.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.05%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/President/Chief Executive Officer/Director
William Lewis
Chief Financial Officer
Sara Bonstein
Chief Operating Officer
Roger Adsett
Chief Accounting Officer
John Goll
Chief Compliance Officer
John Soriano
Other
Martina Flammer
Other
Christine Pellizzari
Other
S. Nicole Schaeffer
Lead Director/Independent Director
David Brennan
Director
Carol Schafer
Independent Director
Alfred Altomari
Independent Director
Elizabeth Anderson
Independent Director
Clarissa Desjardins
Independent Director
Steinar Engelsen
Independent Director
Leo Lee
Independent Director
David McGirr
Independent Director
Melvin Sharoky
  • Dividends
  • Splits
  • Insider Activity
No Data
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Webull offers kinds of Insmed Incorporated stock information, including NASDAQ:INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.